RxDoctor Payments Data

Tiffany Hayes, PA

Medical · Chattanooga, TNNPI 1831356658

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 358 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 31.2% of the total.

$5,352in general payments, 2019–2025

Across 358 payments — averaging $14.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$402
  • Lilly USA, LLC$377
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$253
  • Supernus Pharmaceuticals, Inc.$232
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$5,352100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,352 in reported general payments places this provider in the 85th percentile of 480 medical providers in Tennessee.

See all medical providers in Tennessee

Medicare billing

Part B allowed, 2024
$48,962
Medicare patients
133
Services billed
1,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide73$91,942
OzempicSemaglutide53$77,767
EliquisApixaban28$31,495
TrulicityDulaglutide21$30,598
Repatha SureclickEvolocumab37$29,331
FarxigaDapagliflozin Propanediol27$23,007
Soliqua 100-33Insulin Glargine/Lixisenatide15$19,618
RexultiBrexpiprazole11$17,067
JardianceEmpagliflozin22$14,466
BelsomraSuvorexant14$5,860
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp13$3,256
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,153
Atorvastatin Calcium238$2,789
Enoxaparin Sodium13$2,731
Rosuvastatin Calcium189$2,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$377$122,54094 claims
Novo NordiskOzempic$1,060$77,76753 claims
PfizerEliquis$37$31,49528 claims
AstraZenecaFarxiga$402$23,00727 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$67$19,61815 claims
Otsuka America Pharmaceutical, Inc.Rexulti$221$17,06711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 480 medical providers in Tennessee.

Other medical in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →